1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

US FDA Guidance On Endpoints Incorporating Clinical Outcome Assessments Fulfills Patient-Focused Commitment

 
• By Bridget Silverman
  
Generate a summary of this article
Listen to this article
Beta

Stakeholders can weigh in during 4 May 2023 webinar as US FDA rounds out a PDUFA VI commitment with a draft of the fourth of four methodological guidances on patient-focused drug development.

Doctor woman sitting with male patient at the desk
• Source: Shutterstock

The growing uptake of patient experience data in clinical development programs is reflected in the fourth of four methodological guidance document on patient-focused drug development, a draft guidance on “Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision Making” that touches on a wide range of issues and considerations that have arisen in the course of the maturation of patient-focused drug development from a set of goals to an increasingly established aspect of new drug applications.

The new PFDD document poses situations and points to consider drawn from the FDA’s experience with patient experience data in...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D

  • India Tightens Oversight Of CROs With Mandatory Registration

     
    • By Vibha Sharma

    Contract research organizations (CROs) in India must gear up to comply with new registration requirements coming into effect in April 2025 that aim to enhance the quality and integrity of clinical trials, as well as of any bioavailability and bioequivalence studies conducted by them.

  • Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say

     
    • By Sue Sutter

    The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.

  • How To Decarbonize Pharma R&D

     
    • By Francesca Bruce

    As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.